Resource Type

Journal Article 36

Conference Videos 1

Year

2023 3

2022 2

2021 7

2020 1

2019 5

2018 1

2017 1

2016 3

2015 1

2014 4

2012 2

2011 1

2009 1

2006 1

1999 1

open ︾

Keywords

monoclonal antibody 5

antibody 4

COVID-19 3

SARS-CoV-2 3

polyclonal antibody 3

Antibody response 2

Monoclonal antibody 2

influenza virus 2

neutralizing antibody 2

-acetylglucosamine 1

Nsp9 1

p-NH2-Bn-DTPA 1

p-SCN-Bz-DTPA 1

ADCP 1

Allergic disease 1

Anti-IgE 1

Antibody production 1

Antibody purification 1

Antibody therapy 1

open ︾

Search scope:

排序： Display mode:

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Frontiers of Medicine doi: 10.1007/s11684-023-0996-8

Abstract: Here, we discovered that BGB-A445, a non-ligand-competitive agonistic anti-OX40 antibody currently underdose-dependently and significantly depleted regulatory T cells in vitro and in vivo via antibody-dependentdemonstrated robust and dose-dependent antitumor efficacy, whereas the ligand-competitive anti-OX40 antibodyFurthermore, BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody.

Keywords： BGB-A445     OX40     agonistic antibody     OX40L noncompetitive    

HTML PDF Collect

Passive antibody therapy in emerging infectious diseases

Frontiers of Medicine doi: 10.1007/s11684-023-1021-y

Abstract: Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonalIn addition, the prospects of applying antibody therapy against VOCs was assessed, offering insights

Keywords： SARS-CoV-2     COVID-19     convalescent plasma     hyperimmunoglobulin     neutralizing monoclonal antibodies    

HTML PDF Collect

Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv

Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT

Frontiers of Chemical Science and Engineering 2012, Volume 6, Issue 2,   Pages 216-223 doi: 10.1007/s11705-012-1289-y

Abstract: The objective of this work was to produce a polyclonal antibody against VP26 and use it as a biosensorprotein (rVP26) was produced in (BL21), purified and used for immunizing rabbits to obtain a polyclonal antibody

Keywords： recombinant protein     polyclonal antibody     label-free biosensor     impedance     white spot syndrome virus (WSSV    

HTML PDF Collect

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 83-93 doi: 10.1007/s11684-019-0682-z

Abstract: Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC haveand S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibodyFurthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependent

Keywords： S492R EGFR ectodomain mutation     colorectal cancer     mAb CH12     immunnotherapy    

HTML PDF Collect

Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples

Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA

Frontiers of Environmental Science & Engineering 2011, Volume 5, Issue 3,   Pages 409-416 doi: 10.1007/s11783-011-0349-8

Abstract: The monoclonal antibody with high level of binding affinity for Cd-IEDTA-BSA and high specificity for

Keywords： cadmium     hapten     monoclonal antibody     enzyme-linked immunosorbent assay (ELISA)    

HTML PDF Collect

CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells

Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao

Frontiers of Medicine 2016, Volume 10, Issue 2,   Pages 204-211 doi: 10.1007/s11684-016-0443-1

Abstract: A positive clone of CD176 single-chain variable antibody fragment (scFv) was successfully screened from

Keywords： CD176     Thomsen-Friedenreich antigen     scFv     cancer     therapy     adhesion     metastasis    

HTML PDF Collect

Modified Therapeutic Antibodies: Improving Efficacy Review

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Engineering 2021, Volume 7, Issue 11,   Pages 1529-1540 doi: 10.1016/j.eng.2020.06.030

Abstract: of crystallizable domain (Fc) amino acid alterations; ③ cross-isotype or cross-subclass exchanges; ④ antibody

Keywords： Therapeutic antibody     Modification     Efficacy     Antigen     Antibody–drug conjugate     Bispecific antibody    

HTML PDF Collect

Optimal Antibody Purification Strategies Using Data-Driven Models Article

Songsong Liu, Lazaros G. Papageorgiou

Engineering 2019, Volume 5, Issue 6,   Pages 1077-1092 doi: 10.1016/j.eng.2019.10.011

Abstract:

This work addresses the multiscale optimization of the purification processes of antibody fragmentsnonlinear programming (MINLP) models are proposed to minimize the total cost of goods per gram of the antibody

Keywords： Antibody purification     Multiscale optimization     Antigen-binding fragment     Mixed-integer programming    

HTML PDF Collect

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Frontiers of Medicine 2021, Volume 15, Issue 4,   Pages 644-648 doi: 10.1007/s11684-021-0847-4

Abstract: The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirusA single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibilityIn addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection

Keywords： neutralizing antibody     antibody cocktail     SARS-CoV-2     COVID-19     therapeutic strategy    

HTML PDF Collect

A Novel Human Antibody, HF, against HER2/erb-B2 Obtained by a Computer-Aided Antibody Design Method Article

Chunxia Qiao, Ming Lv, Xinying Li, Xiaoling Lang, Shouqin Lv, Mian Long, Yan Li, Shusheng Geng, Zhou Lin, Beifen Shen , Jiannan Feng

Engineering 2021, Volume 7, Issue 11,   Pages 1566-1576 doi: 10.1016/j.eng.2020.10.024

Abstract: At present, most potential antibody drugs in clinical trials are humanized or fully human.Here, we describe a structure-based computer-aided de novo design technology for human antibody generationcomplementarity determining regions in a suitable immunoglobulin frame, giving birth to a novel anti-HER2 antibody

Keywords： HER2/erb-B2     Human antibody     Computer-aided design    

HTML PDF Collect

From SARS to MERS: evidence and speculation

Hainv Gao,Hangping Yao,Shigui Yang,Lanjuan Li

Frontiers of Medicine 2016, Volume 10, Issue 4,   Pages 377-382 doi: 10.1007/s11684-016-0466-7

Abstract:

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic pathogen. In 2012, the infectious outbreak caused by MERS-CoV in Saudi Arabia has spread to more than 1600 patients in 26 countries, resulting in over 600 deaths. Without a travel history, few clinical and radiological features can reliably differentiate MERS from SARS. But in real world, comparing with SARS, MERS presents more vaguely defined epidemiology, more severe symptoms, and higher case fatality rate. In this review, we summarize the recent findings in the field of MERS-CoV, especially its molecular virology, interspecies mechanisms, clinical features, antiviral therapies, and the further investigation into this disease. As a newly emerging virus, many questions are not fully answered, including the exact mode of transmission chain, geographical distribution, and animal origins. Furthermore, a new protocol needs to be launched to rapidly evaluate the effects of unproven antiviral drugs and vaccine to fasten the clinical application of new drugs.

Keywords： middle east respiratory syndrome     animal origin     cross-species transmission     monoclonal antibody    

HTML PDF Collect

Reduction of rough set attribute based on immune clone selection

LIANG Lin, XU Guang-hua

Frontiers of Mechanical Engineering 2006, Volume 1, Issue 4,   Pages 413-417 doi: 10.1007/s11465-006-0049-4

Abstract: In this method, the approximation quality and attribute set were adopted as evolution object and antibodyOn the basis of the inherent distribution within the immune response, the global optimization of the antibodyMoreover, the diversity of the antibody population was maintained with the affinity maturation and renewalof the antibody.

Keywords： inherent distribution     maturation     evolution     diversity     antibody    

HTML PDF Collect

Antibody Therapies Targeting Complex Membrane Proteins Review

Georgina To´a Salazar, Ziyi Huang, Ningyan Zhang, Xue-Guang Zhang, Zhiqiang An,

Engineering 2021, Volume 7, Issue 11,   Pages 1541-1551 doi: 10.1016/j.eng.2020.11.013

Abstract: conformations of a particular membrane protein, as well as adaptability through engineering into various antibodyion channels, transporters, and membrane-bound enzymes can be addressed by the design of the antigen, antibody-generationstrategies, lead optimization technologies, and antibody modalities.complex membrane proteins with antibodies and discusses the preparation of membrane protein antigens and antibody

Keywords： Antibody therapy     Complex membrane protein     Ion channels     Transporters     Membrane-bound enzymes     GPCRs    

HTML PDF Collect

Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic

Frontiers of Medicine 2022, Volume 16, Issue 6,   Pages 984-990 doi: 10.1007/s11684-022-0930-5

Abstract: Our results revealed that antibody titers in vaccinated participants were significantly higher than those

Keywords： influenza virus     seroprevalence     antibody     COVID-19     cross-sectional study    

HTML PDF Collect

Current State of Monoclonal Antibody Therapy for Allergic Diseases Review

Yan Chen, Wei Wang, Huihui Yuan, Yan Li, Zhe Lv, Ye Cui, Jie Liu, Sun Ying

Engineering 2021, Volume 7, Issue 11,   Pages 1552-1556 doi: 10.1016/j.eng.2020.06.029

Abstract:

Allergic disease is one of the most common chronic diseases, which can affect both children and adults, be often caused by allergen-induced unfavorable immune responses, and initiate various symptoms in different organs, including up-/low-airways and skin, such as asthma, atopic dermatitis, and rhinosinusitis. With increasing prevalence of allergic disease worldwide and their impact on the quality of life, new biological therapeutic approaches for these disorders become hot areas of intensive research. Multiple factors are involved and play important role in the pathogenesis of allergic disease, which can promote or trigger T helper 2 (Th2)-type immune responses, leading to production of the type 2 cytokines and immunoglobulin E (IgE)，the two critical events in the allergic diseases. Using monoclonal antibodies to target these molecules, therefore, might provide possible benefits for the patients suffered from these diseases. Apart of those having approved biologics for allergic diseases, some potential targets such as epithelial-derived alarmins thymic stromal lymphopoietin (TSLP) and interleukin 33 (IL-33) have been also described and proposed to develop monoclonal antibodies against either these cytokines, their receptors, or both. These new and potential targets have substantially enriched the therapeutic opportunities in the field of allergic diseases. The present review aims to briefly outline the role of monoclonal antibodies targeting the cytokines and immunoglobulin involved in the development of allergic diseases, and to discuss the clinical effects of these antibodies.

Keywords： Allergic disease     Monoclonal antibody     Anti-IgE     Cytokines     Clinical trials    

HTML PDF Collect

Title Author Date Type Operation

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Journal Article

Passive antibody therapy in emerging infectious diseases

Journal Article

Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv

Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT

Journal Article

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Journal Article

Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples

Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA

Journal Article

CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells

Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao

Journal Article

Modified Therapeutic Antibodies: Improving Efficacy

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Journal Article

Optimal Antibody Purification Strategies Using Data-Driven Models

Songsong Liu, Lazaros G. Papageorgiou

Journal Article

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Journal Article

A Novel Human Antibody, HF, against HER2/erb-B2 Obtained by a Computer-Aided Antibody Design Method

Chunxia Qiao, Ming Lv, Xinying Li, Xiaoling Lang, Shouqin Lv, Mian Long, Yan Li, Shusheng Geng, Zhou Lin, Beifen Shen , Jiannan Feng

Journal Article

From SARS to MERS: evidence and speculation

Hainv Gao,Hangping Yao,Shigui Yang,Lanjuan Li

Journal Article

Reduction of rough set attribute based on immune clone selection

LIANG Lin, XU Guang-hua

Journal Article

Antibody Therapies Targeting Complex Membrane Proteins

Georgina To´a Salazar, Ziyi Huang, Ningyan Zhang, Xue-Guang Zhang, Zhiqiang An,

Journal Article

Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic

Journal Article

Current State of Monoclonal Antibody Therapy for Allergic Diseases

Yan Chen, Wei Wang, Huihui Yuan, Yan Li, Zhe Lv, Ye Cui, Jie Liu, Sun Ying

Journal Article